Fennec Pharmaceuticals Inc.
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
About
CEO
Mr. Rostislav Raykov
Employees
29
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
68 TW Alexander Drive, Research Triangle Park, NC 27709, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 3, 2025 | — | — | — | — |
| Aug 11, 2025 | — | — | — | — |
| May 12, 2025 | — | — | — | — |
| Mar 17, 2025 | 0.02 | — | — | — |
| Nov 7, 2024 | -0.09 | -0.21 | -0.12 | 133.33% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 4 |
| Average estimate | — | -0.11 | — | -0.16 |
| Low estimate | — | -0.20 | — | -0.53 |
| High estimate | — | -0.04 | — | 0.21 |
| Last year EPS | — | 0.41 | — | -0.09 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-30.000%
Next qtr. (Mar 2025)
-127.440%
Current year
85.550%
Next year (Dec 2025)
-81.720%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 21.25M | 1.54M | — | 170,000 | — |
| Cost of revenue | 1.26M | 86,000 | — | — | — |
| Gross profit | 19.99M | 1.45M | — | — | — |
| Operating expense | |||||
| Research & development | 56,000 | 3.53M | 4.98M | 5.11M | 5.61M |
| Selling general and admin | 32.71M | 20.51M | 12.24M | 12.95M | 7.40M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -13.06M | -22.74M | -17.22M | -17.89M | -13.01M |
| Non operating interest income | |||||
| Income | 441,000 | 195,000 | 54,000 | 87,000 | 315,000 |
| Expense | 3.39M | 978,000 | 126,000 | 9,000 | — |
| Other income expense | -34,000 | -193,000 | -35,000 | 100,000 | -17,000 |
| Pretax income | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M |
| Tax provision | — | — | — | — | — |
| Net income | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M |
| Basic EPS | -0.60 | -0.90 | -0.67 | -0.76 | -0.64 |
| Diluted EPS | -0.60 | -0.90 | -0.67 | -0.76 | -0.64 |
| Basic average shares | 26.57M | 26.28M | 26.01M | 23.70M | 19.96M |
| Diluted average shares | 26.57M | 26.28M | 26.01M | 23.70M | 19.96M |
| EBITDA | -12.33M | -22.39M | -17.19M | -18.20M | -13.01M |
| Net income from continuing op. | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 26.86M | 26.94M | 22.41M | 31.42M | 14.15M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 13.27M | 23.77M | 21.10M | 30.34M | 13.65M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 8.81M | 1.55M | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | 2.16M | 576,000 | — | — | — |
| Prepaid assets | 2.58M | 770,000 | 1.03M | 797,000 | 226,000 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 44,000 | 63,000 | 253,000 | 276,000 | 8,000 |
| Non current assets | |||||
| Properties | — | — | — | — | — |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 6,000 | 211,000 | 27,000 | — | 262,000 |
| Total liabilities | 38.49M | 29.51M | 6.64M | 2.35M | 2.27M |
| Current liabilities | |||||
| Accounts payable | 3.78M | 2.39M | 777,000 | 1.57M | 1.61M |
| Accrued expenses | 3.75M | 2.22M | 877,000 | 776,000 | 659,000 |
| Short term debt | 21,000 | — | — | — | — |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 30.93M | 24.90M | 4.99M | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 144.31M | 142.59M | 140.80M | 140.73M | 106.39M |
| Retained earnings | -219.25M | -203.20M | -179.49M | -162.14M | -144.03M |
| Other shareholders equity | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Total shareholders equity | -11.62M | -2.57M | 15.77M | 29.07M | 11.88M |
| Additional paid in capital | 62.07M | 56.80M | 53.21M | 49.23M | 48.27M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||
| Net Income | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M | -9.89M | -7.05M | -2.79M | -659,000 | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | — | -13.60M | -13.36M | -19.10M | -19.25M | -8.74M | -6.15M | -3.72M | -2.45M | -1.60M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 164,000 | 192,000 | 2.43M | 3.06M | 2.52M | 1.61M | 123,969 | 55,233 | 52,009 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1.54M | -2.29M | — | — | — | — | — |
| Stock-Based Compensation | 5.35M | 4.09M | 3.75M | 2.79M | 2.67M | 1.83M | 1.52M | 615,000 | 97,000 | 627,000 | 62,000 | 326,000 | 250,000 | 2.49M | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 287,000 | 282,000 | 282,000 | 486,000 | 481,000 | 272,000 | 741,000 | 88,000 | — | 434,000 | 25,000 | — | — | -5.33M | -2.65M | -11.10M | 2.32M | 2.61M | -613,000 | -375,798 | -313,293 | — | — | 1 |
| Accounts Receivable | -7.27M | -1.55M | — | — | — | — | — | — | — | — | — | — | — | — | — | 46,000 | — | — | 125,000 | 106,513 | -20,787 | 175,403 | -105,822 | 10,514 |
| Accounts Payable | 1.39M | 1.61M | -794,000 | -41,000 | 580,000 | 177,000 | 611,000 | -54,000 | -11,000 | 96,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -1.58M | -570,000 | -2,000 | -168,000 | -7,000 | 12,000 | -10,000 | -2,000 | 16,000 | -9,000 | — | — | — | — | — | 1,000 | -2.46M | 2.12M | 1.00M | 87,761 | -843,367 | 179,099 | -160,951 | 109,153 |
| Operating Cash Flow | -17.86M | -19.85M | -14.11M | -15.04M | -9.06M | -7.60M | -4.19M | -2.14M | -557,000 | -1.03M | 1.93M | -4.84M | 4.94M | -10.66M | -2.65M | -24.48M | -13.30M | -13.48M | -17.97M | -6.40M | -5.72M | -3.24M | -2.67M | -1.43M |
| Investing Activities | ||||||||||||||||||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -15,000 | -73,000 | -5,000 | -102,000 | -155,270 | -28,211 | -296,735 | -323,199 | -32,316 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -717,902 | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -3.44M | -7.11M | -185,600 | -5.37M | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.18M | 2.26M | — | 6.04M | — | — | — |
| Investing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 24,000 | -15,000 | -75,000 | 1.17M | -1.26M | -7.07M | 4.93M | -5.80M | -323,199 | -32,316 |
| Financing Activities | ||||||||||||||||||||||||
| Long-Term Debt Issuance | 5.00M | 24.94M | 5.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.30M | 1.93M | — | — | — |
| Long-Term Debt Payments | — | -5.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -32,970 | — | — |
| Other Financing Charges | -75,000 | -131,000 | -55,000 | -140,000 | -71,000 | 18,000 | — | — | — | — | — | — | — | — | — | 7,000 | — | -70,000 | -141,000 | -399,801 | — | — | — | — |
| Financing Cash Flow | 4.92M | 19.80M | 4.95M | 31.83M | -71,000 | 18,000 | 27.38M | 5.00M | — | 2.18M | 1.57M | — | 2.57M | 7.19M | — | 7,000 | 23.92M | 6.03M | 8.02M | 24.54M | 1.93M | -32,970 | 12.28M | 1.23M |
| Other Cash Details | ||||||||||||||||||||||||
| End Cash Position | 13.27M | 23.77M | 21.10M | 30.34M | 13.65M | 22.78M | 28.26M | 3.93M | 942,000 | 2.31M | 1.66M | 2.30M | 5.30M | 5.95M | 685,000 | 5.35M | 16.16M | 5.67M | 11.92M | 13.67M | 2.15M | 207,055 | 9.35M | 111,116 |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -17.14M | -18.06M | -14.22M | -15.60M | -9.06M | -7.83M | -3.64M | -2.12M | -1.86M | -1.70M | -2.21M | -2.99M | -3.23M | -1.93M | -4.69M | -10.82M | -13.38M | -13.48M | -12.36M | -6.14M | -5.92M | -3.53M | -3.02M | -1.26M |
Error: Invalid format in Holders JSON file.
Article
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to
Feb 7, 2025
Article
Is the Options Market Predicting a Spike in Adherex Technologies (FENC) Stock?
Investors need to pay close attention to Adherex Technologies (FENC) stock based on the movements in the options market lately.
Jan 24, 2025
Article
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~
Dec 20, 2024
